Terms: = Pancreatic cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Diagnosis
37 results:
1. PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report.
Kong YH; Xu ML; Zhang JJ; Chen GQ; Hong ZH; Zhang H; Dai XX; Ma YF; Zhao XR; Zhang CY; Chen RZ; Xing PF; Zhang LY
World J Gastroenterol; 2024 Mar; 30(9):1237-1249. PubMed ID: 38577174
[TBL] [Abstract] [Full Text] [Related]
2. Therapeutic Potential of Targeting Transforming Growth Factor-beta (TGF-β) and Programmed Death-ligand 1 (PD-L1) in pancreatic cancer.
Pourali G; Zafari N; Velayati M; Mehrabadi S; Maftooh M; Hassanian SM; Mobarhan MG; Ferns GA; Avan A; Khazaei M
Curr Drug Targets; 2023; 24(17):1335-1345. PubMed ID: 38053355
[TBL] [Abstract] [Full Text] [Related]
3. Single-cell mapping reveals several immune subsets associated with liver metastasis of pancreatic ductal adenocarcinoma.
Zhang Z; Zhu XQ; Yang F; Lai NN; Zhu L; Cole K; Hu BY; Li TE; Zhu Y; Zhang LM; Wang S; Zheng Y; Mao H; Zhao Y; Bruns C; Vago R; Tu B; Wong JWH; Fu DL; Qin LX; Dong QZ
Med; 2023 Oct; 4(10):728-743.e7. PubMed ID: 37633269
[TBL] [Abstract] [Full Text] [Related]
4. The prognostic role of epidermal growth factor receptor mutation in completely resected ampullary adenocarcinoma.
Varol U; Cakır E; Aktas S; Altun ZS; Dilek FH; Butun O; Salman T; Unlu AGD; Alacacioglu A; Somali I
Pol J Pathol; 2023; 74(1):18-28. PubMed ID: 37306349
[TBL] [Abstract] [Full Text] [Related]
5. Radical Resection Combined With Intestinal Autotransplantation for Locally Advanced pancreatic cancer After Neoadjuvant Therapy: A Report of 36 Consecutive Cases.
Liang T; Zhang Q; Wu G; Liu C; Bai X; Gao S; Ma T; Sun K; Yan S; Xiao W; Jiang T; Lu F; Zhang Y; Shen Y; Zhang M; Zhang X; Shan J
Ann Surg; 2023 Nov; 278(5):e1055-e1062. PubMed ID: 36727746
[TBL] [Abstract] [Full Text] [Related]
6. Case report: Two PD-L1 positive unresectable advanced pancreatic carcinoma patients with microsatellite stability achieved R0 resection after pd-1 antibody plus chemotherapy as a successful downstaging therapy: A report of two cases.
Shang L; Li P; Fan J; Zhao C; Niu X; Bian Q; Yuan Z; Kong Y; Zhu T; Xu B; Dong J; Xiang H
Front Immunol; 2022; 13():946266. PubMed ID: 36203575
[TBL] [Abstract] [Full Text] [Related]
7. Targeting Tumor Microenvironment in Liver cancers: Rationale, Current Progress, and Future Perspective.
Duda DG
Keio J Med; 2022; 71(3):71. PubMed ID: 36155490
[TBL] [Abstract] [Full Text] [Related]
8. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
Front Immunol; 2022; 13():923031. PubMed ID: 35924241
[TBL] [Abstract] [Full Text] [Related]
9. Single-cell immune signature for detecting early-stage HCC and early assessing anti-pd-1 immunotherapy efficacy.
Shi J; Liu J; Tu X; Li B; Tong Z; Wang T; Zheng Y; Shi H; Zeng X; Chen W; Yin W; Fang W
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101942
[TBL] [Abstract] [Full Text] [Related]
10. A comprehensive analysis of different gene classes in pancreatic cancer: SIGLEC15 may be a promising immunotherapeutic target.
Xu JL; Guo Y
Invest New Drugs; 2022 Feb; 40(1):58-67. PubMed ID: 34515878
[TBL] [Abstract] [Full Text] [Related]
11. Programmed cell death protein-1 inhibitors in the treatment of digestive system tumors in Chinese population: an observational study of effectiveness and safety.
Yang W; Chang L; Guo Q; Chen J; Yu W; Zhang W
Ann Palliat Med; 2021 Aug; 10(8):9015-9024. PubMed ID: 34488388
[TBL] [Abstract] [Full Text] [Related]
12. Antitumor immune response is associated with favorable survival in GEP-NEN G3.
Rosery V; Reis H; Savvatakis K; Kowall B; Stuschke M; Paul A; Dechêne A; Yang J; Zhao B; Borgers A; Kasper S; Schuler M; Cheung PF; Siveke JT
Endocr Relat Cancer; 2021 Sep; 28(10):683-693. PubMed ID: 34472429
[TBL] [Abstract] [Full Text] [Related]
13. Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With cancer.
Jacob JS; Dutra BE; Garcia-Rodriguez V; Panneerselvam K; Abraham FO; Zou F; Ma W; Grivas P; Thompson JA; Altan M; Oliva ICG; Zhang HC; Thomas AS; Wang Y
J Natl Compr Canc Netw; 2021 Aug; 19(12):1415-1424. PubMed ID: 34348238
[TBL] [Abstract] [Full Text] [Related]
14. Serum Soluble PD-L1, PD-L2, and B7-H5 as Potential Diagnostic Biomarkers of Human pancreatic cancer.
Wu W; Xia X; Cheng C; Niu L; Wu J; Qian Y
Clin Lab; 2021 Jun; 67(6):. PubMed ID: 34107622
[TBL] [Abstract] [Full Text] [Related]
15. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade.
Nielsen SR; Strøbech JE; Horton ER; Jackstadt R; Laitala A; Bravo MC; Maltese G; Jensen ARD; Reuten R; Rafaeva M; Karim SA; Hwang CI; Arnes L; Tuveson DA; Sansom OJ; Morton JP; Erler JT
Nat Commun; 2021 Jun; 12(1):3414. PubMed ID: 34099731
[TBL] [Abstract] [Full Text] [Related]
16. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy - A multicentre study of 90 patients from the German Dermatooncology Group.
Grimmelmann I; Momma M; Zimmer L; Hassel JC; Heinzerling L; Pföhler C; Loquai C; Ruini C; Utikal J; Thoms KM; Kähler KC; Eigentler T; Herbst RA; Meier F; Debus D; Berking C; Kochanek C; Ugurel S; Gutzmer R;
Eur J Cancer; 2021 May; 149():1-10. PubMed ID: 33812141
[TBL] [Abstract] [Full Text] [Related]
17. Mechanisms Governing Immunotherapy Resistance in pancreatic Ductal Adenocarcinoma.
Schmiechen ZC; Stromnes IM
Front Immunol; 2020; 11():613815. PubMed ID: 33584701
[TBL] [Abstract] [Full Text] [Related]
18. Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable cancer Response.
Zou F; Abu-Sbeih H; Ma W; Peng Y; Qiao W; Wang J; Shah AY; Glitza Oliva IC; Piha-Paul SA; Thompson JA; Zhang HC; Thomas AS; Wang Y
J Natl Compr Canc Netw; 2020 Dec; 19(6):700-708. PubMed ID: 33316767
[TBL] [Abstract] [Full Text] [Related]
19. KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities.
Luchini C; Paolino G; Mattiolo P; Piredda ML; Cavaliere A; Gaule M; Melisi D; Salvia R; Malleo G; Shin JI; Cargnin S; Terrazzino S; Lawlor RT; Milella M; Scarpa A
J Exp Clin Cancer Res; 2020 Oct; 39(1):227. PubMed ID: 33115526
[TBL] [Abstract] [Full Text] [Related]
20. Immune Checkpoint Inhibitor-Associated Diabetes: A Single-Institution Experience.
Byun DJ; Braunstein R; Flynn J; Zheng J; Lefkowitz RA; Kanbour S; Girotra M
Diabetes Care; 2020 Dec; 43(12):3106-3109. PubMed ID: 33051330
[TBL] [Abstract] [Full Text] [Related]
[Next]